These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

179 related articles for article (PubMed ID: 35240926)

  • 21. Evaluating the potential economic and health impact of rotavirus vaccination in 63 middle-income countries not eligible for Gavi funding: a modelling study.
    Debellut F; Clark A; Pecenka C; Tate J; Baral R; Sanderson C; Parashar U; Atherly D
    Lancet Glob Health; 2021 Jul; 9(7):e942-e956. PubMed ID: 33891885
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Updated cost-effectiveness and risk-benefit analysis of two infant rotavirus vaccination strategies in a high-income, low-endemic setting.
    Bruijning-Verhagen P; van Dongen JAP; Verberk JDM; Pijnacker R; van Gaalen RD; Klinkenberg D; de Melker HE; Mangen MJ
    BMC Med; 2018 Sep; 16(1):168. PubMed ID: 30196794
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Cost-effectiveness of rotavirus vaccination in Albania.
    Ahmeti A; Preza I; Simaku A; Nelaj E; Clark AD; Felix Garcia AG; Lara C; Hoestlandt C; Blau J; Bino S
    Vaccine; 2015 May; 33 Suppl 1():A201-8. PubMed ID: 25919162
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Effects of geographic and economic heterogeneity on the burden of rotavirus diarrhea and the impact and cost-effectiveness of vaccination in Nigeria.
    Anderson JD; Pecenka CJ; Bagamian KH; Rheingans RD
    PLoS One; 2020; 15(5):e0232941. PubMed ID: 32469927
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Estimated impact and cost-effectiveness of rotavirus vaccination in Senegal: A country-led analysis.
    Diop A; Atherly D; Faye A; Lamine Sall F; Clark AD; Nadiel L; Yade B; Ndiaye M; Fafa Cissé M; Ba M
    Vaccine; 2015 May; 33 Suppl 1():A119-25. PubMed ID: 25919151
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Projected health and economic impact of rotavirus vaccination in GAVI-eligible countries: 2011-2030.
    Atherly DE; Lewis KD; Tate J; Parashar UD; Rheingans RD
    Vaccine; 2012 Apr; 30 Suppl 1():A7-14. PubMed ID: 22520139
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Cost-effectiveness of rotavirus vaccination in children under five years of age in 195 countries: A meta-regression analysis.
    Janko MM; Joffe J; Michael D; Earl L; Rosettie KL; Sparks GW; Albertson SB; Compton K; Pedroza Velandia P; Stafford L; Zheng P; Aravkin A; Kyu HH; Murray CJL; Weaver MR
    Vaccine; 2022 Jun; 40(28):3903-3917. PubMed ID: 35643565
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Comparative evaluation of the potential impact of rotavirus versus HPV vaccination in GAVI-eligible countries: a preliminary analysis focused on the relative disease burden.
    Kim SY; Sweet S; Chang J; Goldie SJ
    BMC Infect Dis; 2011 Jun; 11():174. PubMed ID: 21679420
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Mortality reduction benefits and intussusception risks of rotavirus vaccination in 135 low-income and middle-income countries: a modelling analysis of current and alternative schedules.
    Clark A; Tate J; Parashar U; Jit M; Hasso-Agopsowicz M; Henschke N; Lopman B; Van Zandvoort K; Pecenka C; Fine P; Sanderson C
    Lancet Glob Health; 2019 Nov; 7(11):e1541-e1552. PubMed ID: 31607466
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Rotavirus vaccines: targeting the developing world.
    Glass RI; Bresee JS; Turcios R; Fischer TK; Parashar UD; Steele AD
    J Infect Dis; 2005 Sep; 192 Suppl 1():S160-6. PubMed ID: 16088799
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Effects of geographic and economic heterogeneity on the burden of rotavirus diarrhea and the impact and cost-effectiveness of vaccination in Pakistan.
    Rheingans R; Anderson JD; Bagamian KH; Laytner LA; Pecenka CJ; Gilani SSA; Ahmed M
    Vaccine; 2018 Dec; 36(51):7780-7789. PubMed ID: 30007826
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Estimating the economic impact of pneumococcal conjugate, Haemophilus influenzae type b and rotavirus vaccines in India: National and state-level analyses.
    Constenla D; Liu T
    Vaccine; 2019 Dec; 37(52):7547-7559. PubMed ID: 31607600
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Projected impact, cost-effectiveness, and budget implications of rotavirus vaccination in Mongolia.
    Lusvan ME; Debellut F; Clark A; Demberelsuren S; Otgonbayar D; Batjargal T; Purevsuren S; Groman D; Tate J; Pecenka C
    Vaccine; 2019 Feb; 37(6):798-807. PubMed ID: 30639458
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Distributional impact of rotavirus vaccination in 25 GAVI countries: estimating disparities in benefits and cost-effectiveness.
    Rheingans R; Atherly D; Anderson J
    Vaccine; 2012 Apr; 30 Suppl 1():A15-23. PubMed ID: 22520124
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Estimated public health impact of human rotavirus vaccine (HRV) and pneumococcal polysaccharide protein D-conjugate vaccine (PHiD-CV) on child morbidity and mortality in Gavi-supported countries.
    Marijam A; Schuerman L; Izurieta P; Pereira P; Van Oorschot D; Mehta S; Ota MO; Standaert B
    Hum Vaccin Immunother; 2022 Dec; 18(7):2135916. PubMed ID: 36507685
    [TBL] [Abstract][Full Text] [Related]  

  • 36. A review of rotavirus vaccine use in Asia and the Pacific regions: challenges and future prospects.
    Buchy P; Chen J; Zhang XH; Benninghoff B; Lee C; Bibera GL
    Expert Rev Vaccines; 2021 Dec; 20(12):1499-1514. PubMed ID: 33275065
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Experiences with rotavirus vaccines: can we improve rotavirus vaccine impact in developing countries?
    Steele AD; Victor JC; Carey ME; Tate JE; Atherly DE; Pecenka C; Diaz Z; Parashar UD; Kirkwood CD
    Hum Vaccin Immunother; 2019; 15(6):1215-1227. PubMed ID: 30735087
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Economic evaluation of rotavirus vaccination in children of Bhutan.
    Pempa ; Luz ACG; Luangasanatip N; Kingkaew P; Adhikari D; Isaranuwatchai W; Choiphel D; Pecenka C; Debellut F
    Vaccine; 2020 Jul; 38(32):5049-5059. PubMed ID: 32522415
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Cost-effectiveness of rotavirus vaccination in Turkey.
    Koksal T; Akelma AZ; Koksal AO; Kutukoglu I; Ozdemir O; Yuksel CN; Bozkaya D; Catal F; Sari S
    J Microbiol Immunol Infect; 2017 Oct; 50(5):693-699. PubMed ID: 27107612
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Cost-effectiveness and potential impact of rotavirus vaccination in the United States.
    Widdowson MA; Meltzer MI; Zhang X; Bresee JS; Parashar UD; Glass RI
    Pediatrics; 2007 Apr; 119(4):684-97. PubMed ID: 17403839
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.